Drug Profile
Research programme: cell based therapeutics - Endonovo Therapeutics
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator National Aeronautics and Space Administration
- Developer Endonovo Therapeutics
- Class Cell therapies; Stem cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Graft-versus-host disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Graft-versus-host-disease in USA
- 10 Aug 2016 Endonovo files for patent protection with United States patent and Trademark Office (USPTO) for production of biologics for treating chemical and radiation injuries in USA
- 10 Aug 2016 Endonovo has patent protection for "Use of electromagnetic stimulation of cells to produce biological molecules" in USA